Impact Partnership Wealth LLC Makes New $251,000 Investment in Organon & Co. (NYSE:OGN)

Impact Partnership Wealth LLC purchased a new position in shares of Organon & Co. (NYSE:OGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,135 shares of the company’s stock, valued at approximately $251,000.

A number of other large investors also recently made changes to their positions in the business. Mercer Global Advisors Inc. ADV raised its position in shares of Organon & Co. by 1.8% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after buying an additional 546 shares during the period. Ballentine Partners LLC raised its position in Organon & Co. by 3.0% in the second quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after purchasing an additional 552 shares during the period. Atomi Financial Group Inc. raised its position in Organon & Co. by 1.8% in the first quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock valued at $618,000 after purchasing an additional 593 shares during the period. Bill Few Associates Inc. raised its position in Organon & Co. by 5.4% in the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock valued at $253,000 after purchasing an additional 621 shares during the period. Finally, GAMMA Investing LLC raised its position in Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after purchasing an additional 649 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Up 0.1 %

Shares of Organon & Co. stock opened at $17.22 on Friday. The business has a 50-day moving average of $19.83 and a 200-day moving average of $20.12. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The company has a market capitalization of $4.43 billion, a PE ratio of 4.43, a P/E/G ratio of 0.77 and a beta of 0.84. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. The company had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company’s revenue was down .1% on a year-over-year basis. During the same period last year, the firm earned $1.31 earnings per share. As a group, equities analysts forecast that Organon & Co. will post 4.12 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were paid a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a dividend yield of 6.50%. Organon & Co.’s dividend payout ratio is presently 28.79%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and raised their price objective for the company from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.